/* Story-stimulus data, LONGEVITY FRAME (outcome-anchored). Verbatim from uploads/story_stimulus_v1_longevity_frame.md. Same item convention as prebio-stim-notch.jsx. */ const LONGEVITY_POSTURE = { label: "What this version is", paras: [ `The **outcome-anchored** positioning. The story leads with what the world wants: more years lived well. The mechanism appears as the explanation for why this version of longevity is real where most others are aspirational. The patient, and the patient's family, is the protagonist; the clinical asset and platform are the things that let the patient's story be different.`, `**Posture toward the strategic axis.** *"Longevity is what happens when your immune system stays vibrant. We are the only clinical-stage company restoring the organ that decides that."*`, `**Where this lands hardest.** Longevity capital (tech-bro-adjacent funds; Altman-circle; Evolution; Emirates funds; healthspan-thesis allocators). Generalist investors who want a longevity position they can defend in IC. Pharma BD on the aging side of their portfolio. Consumer-facing press. Warm-intro forwarded-PDF readers who don't know what Notch is but know what "stay sharp at 80" means. The longevity-conscious 55-year-old who's already buying supplements and wants to know what's real.`, `**Where this risks losing.** Sophisticated biotech investors who flinch at "longevity" as a category label and want to underwrite mechanism. Pharma BD scouts looking for clinical-asset-grade differentiation. Cell-therapy specialists who'd rather hear "progenitor T-cell therapy in refractory hematologic malignancy" than "vibrant immune system." Clinical investigators who suspect "longevity" of being downstream of patient-care priorities they care about more.`, `**How to use this artifact.** Read past anything that doesn't land. Circle anything you'd actually say at a BIO booth. Tell us what's missing.`, ], }; const LONGEVITY_STIM = [ /* 1 */ { quote: `Aging isn't time. It's what happens when your immune system stops being able to defend you. We're restoring the organ that decides.` }, /* 2 */ { items: [ `★ "Stay young in your immune system; stay young in your life."`, `"The body forgets to age when the immune system stays sharp."`, `★ "Longevity is what happens when the immune system stays vibrant."`, `"We are not extending life. We are extending the years that look like life."`, `"The number on your birthday card doesn't matter. The number of T-cell receptors does."`, `★ "Restoring, not reversing. Restocking, not promising."`, `"Healthier years through a younger immune system."`, ] }, /* 3 */ { items: [ `★ Two grandparents at 75, one playing with grandkids in the yard, one in a hospital bed. Same chronological age. Different immune age.`, `A keychain at 20 (overflowing) and a keychain at 70 (sparse), and a third one being refilled.`, `★ A garden restored to look the way it did decades ago. Not a different garden, the same garden returned.`, `A library whose fire-suppression system finally turned back on.`, `A face you recognize at 80, recognizable because the person is still themselves, still present.`, ] }, /* 4 */ { items: [ `★ "Longevity = wellness with biology paint" → reframe to *"longevity is what happens at the organ-system level when the immune control point is restored. It's medicine, not marketing."*`, `★ "Anti-aging companies are mostly hype" → use the room's skepticism. Acknowledge it; differentiate with the clinical asset.`, `"Healthspan is a buzzword" → reframe to *"healthspan is what shows up when the immune system can still recover. Recovery is measurable."*`, `★ "Longevity is something rich people pay for" → reframe to *"the first indication is for hip-fracture patients in their 80s. The first payers are the ones already paying for the failed recovery."*`, `"Longevity is years from market" → reframe to *"the first asset is in IND-readying. The first market for the longevity thesis is now, not 2040."*`, ] }, /* 5 */ { items: [ `★ **"The GLP-1 for aging."** Carter's own phrase. GLP-1 became a trillion-dollar category by hitting an upstream lever everyone underestimated. Same shape, different organ, different patient.`, `★ **"Premium plumbing for the immune system."** The system was working. The supply line shut off. We reopened the line.`, `**"Vaccines that actually take, at 80."** Restore the responder population and the vaccines invented decades ago start working again.`, `**"The inflection on the curve of healthy aging."** The difference between a slow decline and a plateau.`, `★ **"What gets people to 90 in the shape they want to be in."**`, ] }, /* 6 */ { items: [ `**The fire-suppression system.** Every library has one. When it works, fires happen and get put out. When it stops working, you can clean up the mess for a while. Eventually the library can't keep up. ProTGen reinstalls the fire-suppression.`, `★ **The keychain.** At 20 you carry a keychain with a million different keys for the locks viruses use. At 70 you carry a few thousand. The locks didn't change. The keychain shrunk. We're restocking the keychain.`, `**The river upstream of the city.** Every city's resilience is downstream of a river it doesn't think about. Cut the river off; the city survives a year, then a decade of decline. Restore the river; the city is the same city again.`, `★ **The orchestra and the conductor.** Every musician you knew at 20 is still in the body. The conductor (Notch) stopped showing up. The music is still there. It just isn't in time anymore.`, `**The factory's foreman.** Same shape; same vivid image; same memorable story as the Notch frame.`, ] }, /* 7 */ { items: [ `★ "Everyone is investing in *reversing* aging. We are *restoring* a specific organ. Restoration is more honest than reversal."`, `★ "By age 70, your immune system is older than the rest of you. We can fix the gap."`, `"Most longevity bets are upstream of the cell. Most immune bets are downstream of the cell. Nobody is in the middle. We are."`, `★ "The first 'longevity' indication isn't longevity. It's cancer-survivor immune restoration. Get that right, and longevity follows. Skip it, and longevity is marketing."`, `"There is no FDA-recognized indication called 'longevity.' There is one called 'recovery from major surgery in elderly patients.' We start there."`, `"Every other longevity company is downstream of the question 'how do we measure aging?' We are downstream of the question 'how do we restore the immune system?' Those are different problems."`, ] }, /* 8 */ { items: [ `★ "Why do some 90-year-olds get sick and bounce back like 50-year-olds, while others get pneumonia from a paper cut?"`, `"If aging is about everything, why does fixing one organ change the conversation?"`, `★ "What single organ in your body shut down before you turned 30 and nobody told you?"`, `"Why has every major company in longevity invested in cells, but nobody in clinical-stage organs?"`, `"What's the upstream of every recovery story your family has ever told?"`, ] }, /* 9 */ { items: [ `★ "Everyone has heard of stem cells. Almost no one has heard the word 'thymus' since high school biology. That's the gap."`, `"Everyone knows people slow down with age. Almost no one knows that 'slowing down' is what an unrebuilt immune system looks like from the inside."`, `★ "Everyone has watched a grandparent get frail. Almost no one knows there is a target, a specific, named organ, for what that looks like."`, `"Everyone has felt that longevity sounds too good to be true. Almost no one has been shown the clinical asset behind one company's version of it."`, ] }, /* 10 */ { items: [ `★ "The single organ that explains why your grandfather gets pneumonia from a paper cut."`, `"Why most longevity companies are upstream of the wrong question, and the one that isn't."`, `★ "The forgotten organ, and the company that figured out how to bring it back."`, `"Why your immune system retired in your 20s and what that means for the next 40 years."`, `"Inside the company that asked: what if longevity isn't about cells?"`, ] }, /* 11 */ { items: [ `★ **The library and its fire-suppression system.** The library is your body. The fire-suppression is your immune system. The system stopped working in your 20s. For a while, you can clean up the small fires. Eventually the library is overwhelmed. Restoration isn't about adding books. It's about being able to keep the books you have.`, `**The garden and its gardener.** Once there was a garden. Its gardener (the thymus) retired early. The garden kept blooming for years on what was already in the soil. Then the blooms got smaller. The weeds came. The gardener was always the one who decided what stayed and what didn't. Bring the gardener back. The garden returns.`, `★ **The orchestra's empty podium.** The musicians (immune cells) are still there. The conductor (Notch signaling) stopped showing up. The music is still possible. It just isn't being conducted into time.`, `**The river and the city.** Cut the river off and the city survives for a while on stored water. The wells run lower. The fields parch slowly. Restore the river, not a different river, the same river, and the city is the city again.`, ] }, /* 12 */ { items: [ `★ "Don't say 'diverse adaptive immune repertoire.' Say 'a thousand different keys for the locks viruses use.' At 20 you have a million. At 70 you have a few thousand. We're restocking the keychain."`, `"Don't say 'thymic involution.' Say 'the factory closed.' Don't say 'we restore thymic output.' Say 'we reopen the factory.'"`, `★ "Don't say 'immune-cell exhaustion.' Say 'the same soldiers, three deployments in, with no replacements coming.' Restoration is the replacements coming in."`, `"Don't say 'platform potential.' Say 'one mechanism, six indications. We start with the patient who's hardest to recover. Everything else is downstream of that.'"`, ] }, /* 13 */ { items: [ `★ **Frank, 78, post-hip-fracture.** Standard recovery: weeks of antibiotics, three readmissions, eventually assisted living. Restored immune competence: home in three weeks, back in the garden by spring, playing catch with his great-grandkid in May.`, `**Marie, 65, post-lymphoma.** Four years cancer-free, still on monthly IVIG, vaccine-non-responder. With restored immune competence: off the maintenance protocol, flu shot that actually works, returning to teaching part-time.`, `★ **The CAR-T survivor at year five.** Cancer-free. Living between the treatment that worked and the immune system that didn't reload.`, `**The 78-year-old at Thanksgiving with her grandchildren in flu season.** Cared for, cautious. Her immune system is the only thing between "memorable family year" and "weeks in the hospital."`, ] }, /* 14 */ { items: [ `★ Frank (78, garden, hip fracture).`, `Marie (65, lymphoma, monthly IVIG).`, `★ Carter and the operating team, career builders, multiple cell-therapy ventures, clinical track record.`, `The unnamed scientist on the team who first realized Notch could be targeted, not just blocked.`, `The investor who underwrote at clinical-stage and saw the platform thesis confirm itself.`, ] }, /* 15 */ { items: [ `★ "Stay young in your immune system."`, `"The keychain shrinks by 99 percent."`, `"The factory's foreman retired in your 20s."`, `★ "We're not reversing aging. We're restoring the organ that decides."`, `"Longevity by restoring a vibrant immune system."`, `★ "Same fracture. Different recovery. Different immune system."`, ] }, /* 16 */ { items: [ `Everyone has watched someone they love stay sharp at 80; everyone has watched someone else fade at 70. The difference isn't time. It's recoverability.`, `★ Every potential investor in longevity has felt the tension between believing in the category and underwriting the actual companies in it. We are the one that can be underwritten.`, `Every family with a grandparent in their 80s has felt the difference between "active grandparenting" and "fragile presence." That gap is the unit we're working on.`, `★ Every clinician who treats elderly patients knows the failure mode isn't usually the disease. It's what the disease finds when the immune system has been thin for years.`, ] }, /* 17 */ { items: [ `**Authority.** The longevity field's own arc, Yamanaka, Sinclair, Verdin, Horvath. ProTGen lives downstream of cellular-reprogramming theory at the organ-level resolution. The Cellares partnership. ARMI. The team's prior clinical wins.`, `★ **Counter-authority.** Tech-bros are funding longevity with little evidence and lots of vibes. We have a clinical asset and a Cellares partnership. The antiauthority move is to be the boring grown-up in the room.`, `**Insider absence.** None of the leading longevity companies have a clinical asset in immune restoration. None of the leading immune-therapeutic companies have an aging thesis. The empty middle has one occupant.`, ] }, /* 18 */ { items: [ `★ The thymus is one of the few organs where the involution timetable is measured, predictable, and reversible in animal models. The biology has been characterized for decades. What was missing was the instrument.`, `Cellares automation is the de-risk on the operational layer. Personalized cell therapy has been the failure mode for most ambitious cell-therapy companies. We are pre-solving that.`, `★ ProT-096 is patient-personalized. The progenitor T-cells are derived from the patient's own stem cells. The first indication is the most demanding immune-restoration setting we know.`, `The platform's first indication is one where standard-of-care is supportive care only. The market need is unambiguous.`, ] }, /* 19 */ { items: [ `★ "By 60, your thymus is 5 percent of what it was at 20. Your kidney isn't 5 percent. Your liver isn't. Your heart isn't. The thymus is the only major organ that shrinks by 95 percent on schedule."`, `"More older Americans die from infections they would have shaken off at 30 than from cancer or heart attack. The cause of death on the chart says 'pneumonia.' The cause of death in reality says 'immune system gave up.'"`, `★ "Every year hundreds of thousands of cancer survivors die from infections their old immune system can't fight. The cancer didn't kill them. The treatment that saved them did."`, `"By age 40, you have half the T-cell receptors you had at 20. By 80, ten percent. We are the only company we know of with a clinical-stage way to rebuild that count."`, `"Healthspan in the developed world has not improved at the rate lifespan has. The gap is mostly the immune system."`, ] }, /* 20 */ { items: [ `★ "If we can restore immune competence in post-HSCT cancer survivors, the most damaged immune systems in medicine, we can restore it almost anywhere."`, `"If we can manufacture personalized progenitor T-cells reproducibly at the Cellares scale, we can manufacture them for any indication."`, `★ "If a hip-fracture patient in their 80s can be home in three weeks instead of six months, and the difference is the platform, every elderly recovery setting is downstream of the same lever."`, ] }, /* 21 */ { items: [ `★ ProT-096 IND submission as evidence of execution.`, `Cellares manufacturing-cohort data.`, `★ Thymic-output biomarker readouts as evidence of mechanism translation.`, `Published Notch biology from the team's prior work.`, `The Cellares partnership itself as third-party validation of the platform's seriousness.`, ] }, /* 22 */ { items: [ `★ "Help your future self stay yourself for longer. That's what this funds."`, `"There is a version of medicine in which every cancer survivor gets a Notch-activator regimen as standard post-treatment care, and elderly hip-fracture mortality drops by 40 percent. We are working on that version."`, `★ "Most longevity stories ask you to believe in something abstract. We ask you to believe in a clinical-stage therapy for refractory leukemia patients, and everything else is downstream of that."`, `"The team is real. The asset is real. The biology is real. The category is empty. We are early to something that will not be empty for long."`, ] }, /* 23 */ { items: [ `★ "If I look at Frank, 78, home from the hospital in three weeks playing catch with his great-grandkid in May, I will act. If I look at the 5 million older Americans who will fracture a hip this decade, I freeze."`, `"If I look at Marie, 65, who came off the monthly infusions because her immune system rebuilt itself, I act. If I look at the 18 million cancer survivors living with compromised immune systems, I freeze."`, `★ "Show me the patient. Don't show me the population. The story is the patient whose life looks different because the immune system did."`, ] }, /* 24 */ { items: [ `» For the longevity-investor audience, underneath.`, `★ Being early to a category that survives the next correction.`, `Underwriting a thesis with clinical-stage backing instead of speculation.`, `★ Having an exit story that exists at the pharma BD layer.`, `Being right about which lane in 'longevity' is actually building drugs.`, `» For the longevity-conscious adult / family-of-patient audience, underneath.`, `Not living longer in the wrong shape.`, `★ Being present at 85 in a way that resembles being present at 65.`, `Knowing the people they love can recover from what's coming.`, `★ Real evidence behind the longevity language they hear everywhere.`, ] }, /* 25 */ { items: [ `★ Replace **"anti-aging"** with **"immune-restoration medicine."**`, `★ Replace **"rejuvenation"** with **"restoration."**`, `Replace **"biological age"** with **"immune-system age."**`, `Replace **"lifespan"** with **"healthspan"**, or better, **"years that look like life."**`, `★ Replace **"platform"** with **"control point."**`, `Replace **"longevity"** (when it triggers skepticism) with **"recovery medicine for the patient who needs to come back."**`, ] }, /* 26 */ { items: [ `For the longevity-conscious 55-year-old: *"You're not buying years. You're buying being here, present, functional, with your people, when you're 85."*`, `★ For the longevity investor: *"the company that gives your fund a longevity position you can defend in IC against the cynics."*`, `For the pharma BD: *"the platform you partner with before your competitors realize the category is real."*`, `★ For the family of an elderly patient: *"the gift that means your grandfather is still the person you knew, at the wedding ten years from now."*`, ] }, /* 27 */ { items: [ `★ Longevity-conscious adult: *"I'm someone who invests in the mechanism, not the marketing."*`, `Longevity investor: *"I'm someone who underwrites longevity the way I underwrite oncology, clinical pipeline first, story second."*`, `★ Pharma BD: *"I'm someone who builds for the patient who's still alive but suffering."*`, `Family of a patient: *"I'm someone who took the question seriously enough to find the company actually building the answer."*`, ] }, /* 28 */ { items: [ `★ **Frank's recovery.** Concrete. Specific. Repeatable. Most listeners will tell the story to one other person within a week. That's the simulation in action.`, `**Marie's step off the maintenance protocol.** Quieter, more medical, equally specific. For audiences who need the clinical texture.`, `★ **The investor** who underwrote ProT-096 at clinical-stage, watched the platform expand around it, and named themselves the early-backer story when the category became obvious. Three years later: the second asset closes. Five years later: a strategic acquires.`, `**The pharma BD director** who saw the Notch concept three years ago, passed because it sounded too broad, and now watches the partnership go to her competitor.`, ] }, /* 29 */ { items: [ `★ "Imagine ten years from now. Every cancer survivor gets a Notch-activator regimen as standard post-treatment care. Elderly hip-fracture mortality is down 40 percent. Vaccine response in the over-70 population is solved. The longevity field has finally produced the clinical-stage asset everyone has been promising. ProT-096 is the first asset everyone names when they tell the story."`, `"Imagine the BIO floor five years from now. Every longevity panel has the question 'what's your immune-restoration thesis?' embedded. The companies without an answer feel suddenly thin. The first company to put a clinical-stage asset there set the entire conversation."`, `★ "Imagine your fund's longevity allocation five years from now. Today it's mostly cellular reprogramming bets. Then there was the day the thymic-restoration company moved into the named position. Today's lead investors named themselves having been first."`, ] }, /* 30 */ { items: [ `★ "What's the one organ in your body that's already failing, and you'd never know unless you measured it?"`, `★ "If the difference between aging gracefully and aging painfully isn't exercise or diet, and it's a single organ most adults don't know they have, would you want to hear more?"`, `"Who in your life is one bad infection away from never being the same again?"`, `"What if longevity isn't about adding years to your life, but about keeping the immune system that lets you live them?"`, `★ "What's the upstream of every recovery story you've ever heard?"`, `"If you could fix one organ in your body that decides how the rest of you ages, which one would you pick?"`, `"Why do some 90-year-olds bounce back from pneumonia and others don't?"`, ] }, /* 31 */ { items: [ `★ "Your thymus, the organ that builds your immune defenders, will be 5 percent of its original size by your 60th birthday. No other organ shrinks that fast, and you can't feel it happening."`, `"More older Americans die from infections they would have shaken off at 30 than from cancer or heart attack."`, `★ "Every year, hundreds of thousands of cancer survivors die from infections their old immune systems can't fight. The cancer didn't kill them. The treatment that saved them did."`, `"By age 40, you have half the T-cell receptors you did at 20. By 80, 10 percent. We are the only company we know of with a clinical-stage way to rebuild that count."`, `"Your immune system stopped getting trained reinforcements in your 20s. You've been fighting the rest of your life with the soldiers you had then."`, `★ "Hip-fracture mortality in the over-75 population in the year following the fracture is roughly 25 percent. Most of that is infection. Most of that infection is the immune system, not the surgery."`, ] }, /* 32 */ { items: [ `★ "Where's the longevity company that's actually upstream of every other longevity bet?"`, `★ "What's the asset you can underwrite at clinical-stage today and underwrite at platform-stage in 36 months?"`, `"Why is the entire $5B+ longevity-investment market funded into mechanisms that aren't actually clinical?"`, `"When did 'I want to live to 120' become an acceptable category sentence for an investment thesis?"`, `★ "What if there's a longevity company you could underwrite the way you underwrite an oncology asset, clinical pipeline, ICD-10 code on day one, pharma BD pull?"`, `"How many companies in your pipeline have an IND on a personalized progenitor T-cell therapy with an automated manufacturing partnership?"`, `"What's the difference between 'we're working on aging' and 'we're working on the one organ that gates aging'?"`, ] }, /* 33 */ { items: [ `★ "The longevity-investment thesis has $5 billion committed. Less than 10 percent of that capital is in companies with clinical-stage assets. ProTGen is one of them."`, `"Of the top 12 longevity companies by capital raised, eight have no INDs filed. Two have IND-cleared programs in non-immune indications. One has a clinical asset in immune restoration. That one is ProTGen."`, `★ "Pharma will spend $80 billion on immune-aging within the next decade. The acquisition target list has fewer than 20 companies on it. ProTGen is on it."`, `"Cellular reprogramming raised five billion dollars over five years. Notch-activator immune restoration raised about $20 million. The mechanism gap doesn't justify the funding gap."`, `"Hip-fracture care in the United States is a $20 billion annual cost. A platform that meaningfully reduces complications is a payer-pulled platform on day one."`, `★ "The first indication's annual market opportunity in cancer survivors alone is roughly $30 billion. That's the FIRST indication. The platform addresses six more."`, ] }, ]; Object.assign(window, { LONGEVITY_POSTURE, LONGEVITY_STIM });